On Tuesday, NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY)’s shares declined -23.33% to $0.665.
NovaBay Pharmaceuticals, Inc. (NBY) declared that the registration statement on Form S-3 associated with the Company’s March 2015 private placement has been declared effective by the U.S. Securities and Exchange Commission (SEC).
The registration of these shares causes them to be eligible for open trading in the stock market. The registration statement on Form S-3 and Notice of Effectiveness may be accessed through the SEC’s website at http://www.sec.gov.
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes topical non-antibiotic antimicrobial products for the eye care market. It operates through four segments: Dermatology, Ophthalmology, Urology, and Wound Care.
Ultra Clean Holdings Inc (NASDAQ:UCTT)’s shares dropped -19.18% to $5.52.
Ultra Clean Holdings Inc (UCTT) stated its financial results for the first quarter ended March 27, 2015.
The financial information presented for the first quarter of 2015 comprises two full months of operations of Marchi Thermal Systems, Inc. Ultra Clean attained substantially all of the assets comprising Marchi’s business, and assumed certain liabilities, on February 5, 2015.
Ultra Clean Holdings, Inc. designs, develops, prototypes, engineers, manufactures, and tests subsystems tailored to specific steps in the semiconductor manufacturing process and manufacturing processes in other addressed industries primarily in North America, Asia, and Europe.
At the end of Tuesday’s trade, Novogen Limited (ADR)(NASDAQ:NVGN)‘s shares dipped -16.58% to $7.70.
Novogen Limited (ADR) (NVGN) advises that it has reached definitive contracts to issue about 51 million fully-paid ordinary shares plus one attaching 6-month option and half of one attaching 5-year option for every ordinary share issued, to institutional investors in the United States in a private placement for aggregate gross proceeds of about AU$15,500,000 (“Placement”). The closing of the Placement is predictable to occur on or about 24 April 2015 and is subject to satisfaction of customary closing conditions. The issue of the attaching options under the Placement is subject to shareholder approval.
Novogen Limited is engaged in the pharmaceutical research and development business in Australia. The company has primarily two drug technology platforms, which comprise super-benzopyrans (SBPs) and anti-tropomyosins (ATMs).
GulfMark Offshore, Inc. (NYSE:GLF), ended its Tuesday’s trading session with -15.16% loss, and closed at $13.88.
GulfMark Offshore, Inc. (GLF) declared its results of operations for the three-month period ended March 31, 2015. For the first quarter ended March 31, 2015, revenue was $89.1 million, and net loss was $5.1 million, or $0.21 per diluted share. Comprised of in the quarterly results is one special item that totals $0.01 per diluted share. Quarterly loss before this special item was $0.20 per diluted share.
GulfMark Offshore, Inc. provides offshore marine support and transportation services primarily to the companies involved in the offshore exploration and production of oil and natural gas.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
